The prevalence of cerebral small vessel disease nearly doubled over 7.5 years in neurologically asymptomatic patients with ...

The diagnosis of celiac disease in patients with T1D is challenging due to the common asymptomatic or oligosymptomatic presentation and fluctuating antibody levels. Researchers conducted this ...

Take the type 1 diabetes (T1D) space, as one example. Today, new and exciting advancements are working to reduce barriers, increase access and expand optionality when it comes to early T1D ...

Boston 25′s own Mark Ockerbloom and Rachel Keller hosted the 43rd annual T1D Greater New England Gala on Saturday night.

Community members gathered at the Locust Country Club Saturday evening for the annual Breakthrough T1D Gala, which raises money for Type 1 Diabetes research and prevention. READ MORE: https ...

Vertex Pharmaceuticals has discontinued the development of VX-264, a type 1 diabetes (T1D) cell therapy delivered via an ...

The Breakthrough T1D Gala at Pendry Newport Beach raised nearly $1M for T1D, uniting top OC philanthropists for a night of ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Founded in 1970 by families whose loved ones had been diagnosed with type 1 diabetes (T1D), Breakthrough T1D, formerly JDRF, is a tax-exempt nonprofit 501(c)3 organization, opening doors that were ...